Method of treating inflammation using natural compounds and/or diet
US-2018133194-A1 · May 17, 2018 · US
US11020372B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11020372-B2 |
| Application number | US-201615078590-A |
| Country | US |
| Kind code | B2 |
| Filing date | Mar 23, 2016 |
| Priority date | Mar 24, 2015 |
| Publication date | Jun 1, 2021 |
| Grant date | Jun 1, 2021 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The invention relates to novel methods and compositions for safely reducing negative side effects of cancer treatments. These methods and compositions comprise administering to a patient a composition comprising one or more of the following: curcumin (derived from turmeric), epigallocatechin-3-gallate (EGCG, enriched in green tea), glucosinolates (enriched in cruciferous vegetables) and/or derivatives thereof, such as sulforaphane (SFN), alone or combined with a ketogenic diet or a modified ketogenic diet. Also the current invention relates to a composition comprising medium chain triglycerides (MCT), Epigallocatechin-3-gallate, curcumin, compositions comprising glucosinolates and/or derivatives thereof, such as sulforaphane (SFN). The invention provides that administering a composition comprising curcumin, EGCG, sulforaphane, alone or combined with a ketogenic diet or a modified ketogenic diet (low carbohydrate diet) alone or supplemented with MCT improves resistance of normal cells to cytotoxicity of cancer treatments, in turn, reducing their negative side effects. Increasing normal cells, tissues or organs' resistance to chemotherapeutic agents, the invention improves patients' tolerance to anti-cancer treatments' toxicity, which, in turn, contributes to enhance their efficacy, leading to increased survival of the subject treated with the current invention.
Opening claim text (preview).
What is claimed: 1. A method for managing negative side effects of chemotherapy, radiation therapy, or both, in a subject having cancer, wherein said method comprises administering an effective amount of: (a) epigallocatechin-3-gallate (EGCG), (b) curcumin, and (c) sulforaphane (SFN) to a subject having cancer and undergoing chemotherapy, radiation therapy, or both, for treatment of the cancer, wherein said administering delays, inhibits, or reverses a negative side effect of the chemotherapy, radiation therapy, or both. 2. The method of claim 1 , wherein the EGCG, curcumin and SFN are provided as powder, capsules, tablets, caplets, gel, oil, liquid, emulsion, drink, liquid food product or solid food product. 3. The method of claim 2 , wherein the EGCG, curcumin, and SFN are administered in the form of a unit dosage or separate formulations administered to the subject simultaneously or sequentially. 4. The method of claim 1 , wherein the SFN is administered to the subject in the form of broccoli sprouts or broccoli sprout powder. 5. The method of claim 1 , further comprising administering (d) a medium chain triglyceride (MCT) to the subject. 6. The method of claim 5 , wherein the subject is on a ketogenic diet or modified ketogenic diet. 7. The method of claim 1 , wherein the subject is on a ketogenic diet or modified ketogenic diet. 8. The method of claim 1 , wherein the EGCG, curcumin, and SFN are administered together in a composition that is orally administered to the subject. 9. The method of claim 1 , wherein the treatment comprises chemotherapy. 10. The method of claim 1 , wherein the treatment comprises radiation therapy. 11. The method of claim 1 , wherein the negative side effect is one or more negative side effects selected from among: anemia, leukopenia, thrombocytopenia, nephrotoxicity, hepatotoxicity, neurotoxicity, peripheral neuropathy, and chemotoxicity to endogenous stem cells. 12. The method of claim 1 , wherein the subject is human. 13. The method of claim 1 , wherein the subject is a non-human animal. 14. The method of claim 1 , wherein the negative side effect is one or more negative side effects selected from among: anemia, leukopenia, and peripheral neuropathy. 15. The method of claim 14 , wherein said administering comprises orally administering a composition to the subject, wherein the composition comprises each of the EGCG, curcumin, and SFN. 16. The method of claim 9 , wherein the chemotherapy comprises oxaliplatin or paclitaxel. 17. The method of claim 9 , wherein the chemotherapy comprises temozolomide. 18. The method of claim 9 , wherein the chemotherapy comprises fluorouracil. 19. The method of claim 1 , wherein the method further comprises orally administering a ketone body or ketone ester to the subject. 20. The method of claim 4 , wherein the method further comprises orally administering a ketone body or ketone ester to the subject.
of acids having a carboxyl group bound to a chain of seven or more carbon atoms · CPC title
Fatty acids or derivatives thereof; Fats or oils · CPC title
using additives (addition of substantially indigestible substances A23L33/21) · CPC title
Plant extracts, their artificial duplicates or their derivatives · CPC title
Ketones · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.